We confirmed a significant decrease of IL10+ CLL B cells in anti-IL10-treated PBMCs (P = 0.0312) and of TGFβ1+ CLL B cells in SB431542-treated PBMCs (P = 0.0156), suggesting that both treatments specifically and negatively modulate the expression of their respective intracellular cytokines (Fig. S4D). The gene discussed is TGFB1; the disease is B-cell chronic lymphocytic leukemia.